60. Itoh, G.; Takagane, K.; Fukushi, Y.; Kuriyama, S.; Umakoshi, M.; Goto, A.; Yanagihara, K.; Yashiro, M.; Tanaka, M. Cancer-associated fibroblasts educate normal fibroblasts to facilitate cancer cell spreading and T-cell suppression. *Mol. Oncol.* **2021**, *16*, 166–187. [CrossRef]

61. Sasaki, Y.; Takagane, K.; Konno, T.; Itoh, G.; Kuriyama, S.; Yanagihara, K.; Yashiro, M.; Yamada, S.; Murakami, S.; Tanaka, M. Expression of asporin reprograms cancer cells to acquire resistance to oxidative stress. *Cancer Sci.* **2021**, *112*, 1251–1261. [CrossRef]

62. Chi, L.-H.; Chang, W.-M.; Chang, Y.-C.; Chan, Y.-C.; Tai, C.-C.; Leung, K.-W.; Chen, C.-L.; Wu, A.T.; Lai, T.-C.; Li, Y.-C.; et al. Global Proteomics-based Identification and Validation of Thymosin Beta-4 X-Linked as a Prognostic Marker for Head and Neck Squamous Cell Carcinoma. *Sci. Rep.* **2017**, *7*, 1–13. [CrossRef]

63. Duerr, E.-M.; Mizukami, Y.; Ng, A.; Xavier, R.J.; Kikuchi, H.; Deshpande, V.; Warshaw, A.L.; Glickman, J.; Kulke, M.H.; Chung, D.C. Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis. *Endocr. Relat. Cancer* **2008**, *15*, 243–256. [CrossRef]

64. Hirata, N.; Yamada, S.; Shoda, T.; Kurihara, M.; Sekino, Y.; Kanda, Y. Sphingosine-1-phosphate promotes expansion of cancer stem cells via S1PR3 by a ligand-independent Notch activation. *Nat. Commun.* **2014**, *5*, 4806. [CrossRef] [PubMed]

65. Yang, C.; Yamashita, M.; Suda, T. A Novel Function of Sphingolipid Signaling via S1PR3 in Hematopoietic and Leukemic Stem Cells. *Blood Cancer Discov.* **2020**, *2*, 3–5. [CrossRef] [PubMed]

66. Watters, R.J.; Wang, H.-G.; Sung, S.-S.; Loughran, T.P.; Liu, X. Targeting sphingosine-1-phosphate receptors in cancer. *Anti-Cancer Agents Med. Chem.* **2011**, *11*, 810–817. [CrossRef] [PubMed]

67. Chen, X.; Fu, Y.; Xu, H.; Teng, P.; Xie, Q.; Zhang, Y.; Yan, C.; Xu, Y.; Li, C.; Zhou, J.; et al. SOX5 predicts poor prognosis in lung adenocarcinoma and promotes tumor metastasis through epithelial-mesenchymal transition. *Oncotarget* **2017**, *9*, 10891–10904. [CrossRef] [PubMed]

68. Tanaka, H.; Kanda, M.; Miwa, T.; Umeda, S.; Sawaki, K.; Tanaka, C.; Kobayashi, D.; Hayashi, M.; Yamada, S.; Nakayama, G.; et al. G-protein subunit gamma-4 expression has potential for detection, prediction and therapeutic targeting in liver metastasis of gastric cancer. *Br. J. Cancer* **2021**, *125*, 220–228. [CrossRef] [PubMed]

69. Laurberg, J.R.; Jensen, J.B.; Schepeler, T.; Borre, M.; Ørntoft, T.F.; Dyrskjøt, L. High expression of GEM and EDNRA is associated with metastasis and poor outcome in patients with advanced bladder cancer. *BMC Cancer* **2014**, *14*, 1–10. [CrossRef]

70. Kashiwagi, E.; Shiota, M.; Yokomizo, A.; Itsumi, M.; Inokuchi, J.; Uchiumi, T.; Naito, S. Prostaglandin receptor EP3 mediates growth inhibitory effect of aspirin through androgen receptor and contributes to castration resistance in prostate cancer cells. *Endocr. Relat. Cancer* **2013**, *20*, 431–441. [CrossRef]

71. Fa, J. Dynamin 3 overexpression suppresses the proliferation, migration and invasion of cervical cancer cells. *Oncol. Lett.* **2021**, *22*, 1–8. [CrossRef]

72. Hu, M.; Gu, J.; Su, W.; Zhang, Z.; Zhu, B.; Wang, Q.; Xing, C. DNM1: A Prognostic Biomarker Associated with Immune Infiltration in Colon Cancer—A Study Based on TCGA Database. *BioMed Res. Int.* **2021**, *2021*, 1–9. [CrossRef]

73. Rao, D.; Hyun, T.S.; Kumar, P.D.; Mizukami, I.F.; Rubin, M.A.; Lucas, P.; Sanda, M.G.; Ross, T.S. Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival. *J. Clin. Investig.* **2002**, *110*, 351–360. [CrossRef]

74. Sheridan, M.; Ogretmen, B. The Role of Ceramide Metabolism and Signaling in the Regulation of Mitophagy and Cancer Therapy. *Cancers* **2021**, *13*, 2475. [CrossRef] [PubMed]

75. Schömel, N.; Gruber, L.; Alexopoulos, S.J.; Trautmann, S.; Olzomer, E.M.; Byrne, F.L.; Hoehn, K.L.; Gurke, R.; Thomas, D.; Ferreirós, N.; et al. UGCG overexpression leads to increased glycolysis and increased oxidative phosphorylation of breast cancer cells. *Sci. Rep.* **2020**, *10*, 8182. [CrossRef] [PubMed]

76. Suzuki, M.; Cao, K.; Kato, S.; Mizutani, N.; Tanaka, K.; Arima, C.; Tai, M.C.; Nakatani, N.; Yanagisawa, K.; Takeuchi, T.; et al. CERS6 required for cell migration and metastasis in lung cancer. *J. Cell. Mol. Med.* **2020**, *24*, 11949–11959. [CrossRef] [PubMed]

77. Singh, R.R.; Kunkalla, K.; Qu, C.; Schlette, E.; Neelapu, S.S.; Samaniego, F.; Vega, F. ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. *Oncogene* **2011**, *30*, 4874–4886. [CrossRef] [PubMed]

78. Zhang, Q.; Zhu, M.; Cheng, W.; Xing, R.; Li, W.; Zhao, M.; Xu, L.; Li, E.; Luo, G.; Lu, Y. Downregulation of 425G>A variant of calcium-binding protein S100A14 associated with poor differentiation and prognosis in gastric cancer. *J. Cancer Res. Clin. Oncol.* **2014**, *141*, 691–703. [CrossRef] [PubMed]

79. Bharadwaj, A.; Bydoun, M.; Holloway, R.; Waisman, D. Annexin A2 Heterotetramer: Structure and Function. *Int. J. Mol. Sci.* **2013**, *14*, 6259–6305. [CrossRef]

80. Hitchcock, J.K.; Katz, A.A.; Schäfer, G. Dynamic reciprocity: The role of annexin A2 in tissue integrity. *J. Cell Commun. Signal.* **2014**, *8*, 125–133. [CrossRef]

81. Taylor, J.R.; Fernandez, D.J.; Thornton, S.M.; Skeate, J.; Lühen, K.P.; Da Silva, D.M.; Langen, R.; Kast, W.M. Heterotetrameric annexin A2/S100A10 (A2t) is essential for oncogenic human papillomavirus trafficking and capsid disassembly, and protects virions from lysosomal degradation. *Sci. Rep.* **2018**, *8*, 1–15. [CrossRef]

82. Zhang, J.; Guo, B.; Zhang, Y.; Cao, J.; Chen, T. Silencing of the annexin II gene down-regulates the levels of S100A10, c-Myc, and plasmin and inhibits breast cancer cell proliferation and invasion. *Saudi Med. J.* **2010**, *31*, 374–381.

83. Shen, D.; Nooraie, F.; Elshimali, Y.; Lonsberry, V.; He, J.; Bose, S.; Chia, D.; Seligson, D.; Chang, H.R.; Goodglick, L. Decreased expression of annexin A1 is correlated with breast cancer development and progression as determined by a tissue microarray analysis. *Hum. Pathol.* **2006**, *37*, 1583–1591. [CrossRef]
84. Chua, C.E.L.; Tang, B.L. The role of the smallGTPase Rab31 in cancer. *J. Cell. Mol. Med.* **2014**, *19*, 1–10. [CrossRef] [PubMed]

85. Zhao, Z.; Liu, X.-F.; Wu, H.-C.; Zou, S.-B.; Wang, J.-Y.; Ni, P.-H.; Chen, X.-H.; Fan, Q.-S. Rab5a overexpression promoting ovarian cancer cell proliferation may be associated with APPL1-related epidermal growth factor signaling pathway. *Cancer Sci.* **2010**, *101*, 1454–1462. [CrossRef] [PubMed]

86. Yang, P.-S.; Yin, P.-H.; Tseng, L.-M.; Yang, C.-H.; Hsu, C.-Y.; Lee, M.-Y.; Horng, C.-F.; Chi, C.-W. Rab5A is associated with axillary lymph node metastasis in breast cancer patients. *Cancer Sci.* **2011**, *102*, 2172–2178. [CrossRef] [PubMed]

87. Yang, T.; Zhiheng, H.; Zhanhuai, W.; Qian, X.; Yue, L.; Xiaoxu, G.; Jingsun, W.; Shu, Z.; Kefeng, D. Increased RAB31 Expression in Cancer-Associated Fibroblasts Promotes Colon Cancer Progression Through HGF-MET Signaling. *Front. Oncol.* **2020**, *10*, 1747. [CrossRef]

88. Hong, D.; Fritz, A.J.; Finstad, K.H.; Fitzgerald, M.P.; Weinheimer, A.; Viens, A.L.; Ramsey, J.; Stein, J.L.; Lian, J.B.; Stein, G.S. Suppression of Breast Cancer Stem Cells and Tumor Growth by the RUNX1 Transcription Factor. *Mol. Cancer Res.* **2018**, *16*, 1952–1964. [CrossRef]

89. Zhao, Z.; Liang, S.; Sun, F. LncRNA DLX6-AS1 Promotes Malignant Phenotype and Lymph Node Metastasis in Prostate Cancer by Inducing LARGE Methylation. *Front. Oncol.* **2020**, *10*, 1172. [CrossRef]

90. Wu, Q.; Ma, J.; Meng, W.; Hui, P. DLX6-AS1 promotes cell proliferation, migration and EMT of gastric cancer through FUS-regulated MAP4K1. *Cancer Biol. Ther.* **2019**, *21*, 17–25. [CrossRef]

91. Zhao, X.; Wang, J.; Zhu, R.; Zhang, J.; Zhang, Y. DLX6-AS1 activated by H3K4me1 enhanced secondary cisplatin resistance of lung squamous cell carcinoma through modulating miR-181a-5p/miR-382-5p/CELF1 axis. *Sci. Rep.* **2021**, *11*, 1–13. [CrossRef]

92. Hodgkinson, K.; Forrest, L.A.; Vuong, N.; Garson, K.; Djordjevic, B.; Vanderhyden, B.C. GREB1 is an estrogen receptor-regulated tumour promoter that is frequently expressed in ovarian cancer. *Oncogene* **2018**, *37*, 5873–5886. [CrossRef]

93. Hu, J.; Tian, J.; Zhu, S.; Sun, L.; Yu, J.; Tian, H.; Dong, Q.; Luo, Q.; Jiang, N.; Niu, Y.; et al. Sox5 contributes to prostate cancer metastasis and is a master regulator of TGF-β-induced epithelial mesenchymal transition through controlling Twist1 expression. *Br. J. Cancer* **2017**, *118*, 88–97. [CrossRef]

94. Chen, Y.; Yang, L.; Qin, Y.; Liu, S.; Qiao, Y.; Wan, X.; Zeng, H.; Tang, X.; Liu, M.; Hou, Y. Effects of differential distributed-JUP on the malignancy of gastric cancer. *J. Adv. Res.* **2020**, *28*, 195–208. [CrossRef] [PubMed]

95. Sun, C.; Ban, Y.; Wang, K.; Sun, Y.; Zhao, Z. SOX5 promotes breast cancer proliferation and invasion by transactivation of EZH2. *Oncol. Lett.* **2019**, *17*, 2754–2762. [CrossRef] [PubMed]

96. Du, F.; Li, X.; Feng, W.; Qiao, C.; Chen, J.; Jiang, M.; Qiu, Z.; Qian, M.; Tian, D.; Nie, Y.; et al. SOX13 promotes colorectal cancer metastasis by transactivating SNAI2 and c-MET. *Oncogene* **2020**, *39*, 3522–3540. [CrossRef] [PubMed]

97. Jiao, H.; Fang, F.; Fang, T.; You, Y.; Feng, M.; Wang, X.; Yin, Z.; Zhao, W. SOX13 regulates cancer stem-like properties and tumorigenicity in hepatocellular carcinoma cells. *Am. J. Cancer Res.* **2021**, *11*, 760–772. [PubMed]

98. Yamaguchi, M.; Watanabe, Y.; Ohtani, T.; Uezumi, A.; Mikami, N.; Nakamura, M.; Sato, T.; Ikawa, M.; Hoshino, M.; Tsuchida, K.; et al. Calcitonin Receptor Signaling Inhibits Muscle Stem Cells from Escaping the Quiescent State and the Niche. *Cell Rep.* **2015**, *13*, 302–314. [CrossRef]

99. Li, H.; Liu, P.; Xu, S.; Li, Y.; Dekker, J.D.; Li, B.; Fan, Y.; Zhang, Z.; Hong, Y.; Yang, G.; et al. FOXP1 controls mesenchymal stem cell commitment and senescence during skeletal aging. *J. Clin. Investig.* **2017**, *127*, 1241–1253. [CrossRef]

100. Simmons, J.; Pierce, C.J.; Al-Ejeh, F.; Boyle, G.M. MITF and BRN2 contribute to metastatic growth after dissemination of melanoma. *Sci. Rep.* **2017**, *7*, 1–12. [CrossRef]

101. Carreira, S.; Goodall, J.; Denat, L.; Rodriguez, M.; Nuciforo, P.; Hoek, K.S.; Testori, A.; LaRue, L.; Goding, C.R. Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. *Genes Dev.* **2006**, *20*, 3426–3439. [CrossRef]

102. Travnickova, J.; Wojciechowska, S.; Khamseh, A.; Gautier, P.; Brown, D.V.; Lefevre, T.; Brombin, A.; Ewing, A.; Capper, A.; Spitzer, M.; et al. Zebrafish MITF-Low Melanoma Subtype Models Reveal Transcriptional Subclusters and MITF-Independent Residual Disease. *Cancer Res.* **2019**, *79*, 5769–5784. [CrossRef]

103. Hoek, K.S.; Goding, C.R. Cancer stem cells versus phenotype-switching in melanoma. *Pigment. Cell Melanoma Res.* **2010**, *23*, 746–759. [CrossRef]

104. Johannes, L. The Cellular and Chemical Biology of Endocytic Trafficking and Intracellular Delivery—The GL-Lect Hypothesis. *Molecules* **2021**, *26*, 3299. [CrossRef] [PubMed]

105. Christenson, L. Steroidogenic acute regulatory protein (StAR) and the intramitochondrial translocation of cholester-ol. *Biochim. Biophys. Acta Mol. Cell Biol. Lipids* **2000**, *1529*, 175–187.

106. Wiedenmann, B.; Franke, W.W.; Kuhn, C.; Moll, R.; E Gould, V. Synaptophysin: A marker protein for neuroendocrine cells and neoplasms. *Proc. Natl. Acad. Sci. USA* **1986**, *83*, 3500–3504. [CrossRef] [PubMed]

107. Faillot, S.; Assie, G. ENDOCRINE TUMOURS: The genomics of adrenocortical tumors. *Eur. J. Endocrinol.* **2016**, *174*, R249–R265. [CrossRef]

108. Brondani, V.; Lacombe, A.; Mariani, B.; Montenegro, L.; Soares, I.; Bezerra-Neto, J.; Tanno, F.; Srougi, V.; Chambo, J.; Mendonca, B.; et al. Low Protein Expression of both ATRX and ZNRF3 as Novel Negative Prognostic Markers of Adult Adrenocortical Carcinoma. *Int. J. Mol. Sci.* **2021**, *22*, 1238. [CrossRef]

109. Bai, X.; Fisher, D.E.; Flaherty, K.T. Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways. *Nat. Rev. Clin. Oncol.* **2019**, *16*, 549–562. [CrossRef]
84. Chua, C.E.L.; Tang, B.L. The role of the smallGTPase Rab31 in cancer. *J. Cell. Mol. Med.* **2014**, *19*, 1–10. [CrossRef] [PubMed]

85. Zhao, Z.; Liu, X.-F.; Wu, H.-C.; Zou, S.-B.; Wang, J.-Y.; Ni, P.-H.; Chen, X.-H.; Fan, Q.-S. Rab5a overexpression promoting ovarian cancer cell proliferation may be associated with APPL1-related epidermal growth factor signaling pathway. *Cancer Sci.* **2010**, *101*, 1454–1462. [CrossRef] [PubMed]

86. Yang, P.-S.; Yin, P.-H.; Tseng, L.-M.; Yang, C.-H.; Hsu, C.-Y.; Lee, M.-Y.; Horng, C.-F.; Chi, C.-W. Rab5A is associated with axillary lymph node metastasis in breast cancer patients. *Cancer Sci.* **2011**, *102*, 2172–2178. [CrossRef] [PubMed]

87. Yang, T.; Zhiheng, H.; Zhanhuai, W.; Qian, X.; Yue, L.; Xiaoxu, G.; Jingsun, W.; Shu, Z.; Kefeng, D. Increased RAB31 Expression in Cancer-Associated Fibroblasts Promotes Colon Cancer Progression Through HGF-MET Signaling. *Front. Oncol.* **2020**, *10*, 1747. [CrossRef]

88. Hong, D.; Fritz, A.J.; Finstad, K.H.; Fitzgerald, M.P.; Weinheimer, A.; Viens, A.L.; Ramsey, J.; Stein, J.L.; Lian, J.B.; Stein, G.S. Suppression of Breast Cancer Stem Cells and Tumor Growth by the RUNX1 Transcription Factor. *Mol. Cancer Res.* **2018**, *16*, 1952–1964. [CrossRef]

89. Zhao, Z.; Liang, S.; Sun, F. LncRNA DLX6-AS1 Promotes Malignant Phenotype and Lymph Node Metastasis in Prostate Cancer by Inducing LARGE Methylation. *Front. Oncol.* **2020**, *10*, 1172. [CrossRef]

90. Wu, Q.; Ma, J.; Meng, W.; Hui, P. DLX6-AS1 promotes cell proliferation, migration and EMT of gastric cancer through FUS-regulated MAP4K1. *Cancer Biol. Ther.* **2019**, *21*, 17–25. [CrossRef]

91. Zhao, X.; Wang, J.; Zhu, R.; Zhang, J.; Zhang, Y. DLX6-AS1 activated by H3K4me1 enhanced secondary cisplatin resistance of lung squamous cell carcinoma through modulating miR-181a-5p/miR-382-5p/CELF1 axis. *Sci. Rep.* **2021**, *11*, 1–13. [CrossRef]

92. Hodgkinson, K.; Forrest, L.A.; Vuong, N.; Garson, K.; Djordjevic, B.; Vanderhyden, B.C. GREB1 is an estrogen receptor-regulated tumour promoter that is frequently expressed in ovarian cancer. *Oncogene* **2018**, *37*, 5873–5886. [CrossRef]

93. Hu, J.; Tian, J.; Zhu, S.; Sun, L.; Yu, J.; Tian, H.; Dong, Q.; Luo, Q.; Jiang, N.; Niu, Y.; et al. Sox5 contributes to prostate cancer metastasis and is a master regulator of TGF-β-induced epithelial mesenchymal transition through controlling Twist1 expression. *Br. J. Cancer* **2017**, *118*, 88–97. [CrossRef]

94. Chen, Y.; Yang, L.; Qin, Y.; Liu, S.; Qiao, Y.; Wan, X.; Zeng, H.; Tang, X.; Liu, M.; Hou, Y. Effects of differential distributed-JUP on the malignancy of gastric cancer. *J. Adv. Res.* **2020**, *28*, 195–208. [CrossRef] [PubMed]

95. Sun, C.; Ban, Y.; Wang, K.; Sun, Y.; Zhao, Z. SOX5 promotes breast cancer proliferation and invasion by transactivation of EZH2. *Oncol. Lett.* **2019**, *17*, 2754–2762. [CrossRef] [PubMed]

96. Du, F.; Li, X.; Feng, W.; Qiao, C.; Chen, J.; Jiang, M.; Qiu, Z.; Qian, M.; Tian, D.; Nie, Y.; et al. SOX13 promotes colorectal cancer metastasis by transactivating SNAI2 and c-MET. *Oncogene* **2020**, *39*, 3522–3540. [CrossRef] [PubMed]

97. Jiao, H.; Fang, F.; Fang, T.; You, Y.; Feng, M.; Wang, X.; Yin, Z.; Zhao, W. SOX13 regulates cancer stem-like properties and tumorigenicity in hepatocellular carcinoma cells. *Am. J. Cancer Res.* **2021**, *11*, 760–772. [PubMed]

98. Yamaguchi, M.; Watanabe, Y.; Ohtani, T.; Uezumi, A.; Mikami, N.; Nakamura, M.; Sato, T.; Ikawa, M.; Hoshino, M.; Tsuchida, K.; et al. Calcitonin Receptor Signaling Inhibits Muscle Stem Cells from Escaping the Quiescent State and the Niche. *Cell Rep.* **2015**, *13*, 302–314. [CrossRef]

99. Li, H.; Liu, P.; Xu, S.; Li, Y.; Dekker, J.D.; Li, B.; Fan, Y.; Zhang, Z.; Hong, Y.; Yang, G.; et al. FOXP1 controls mesenchymal stem cell commitment and senescence during skeletal aging. *J. Clin. Investig.* **2017**, *127*, 1241–1253. [CrossRef]

100. Simmons, J.; Pierce, C.J.; Al-Ejeh, F.; Boyle, G.M. MITF and BRN2 contribute to metastatic growth after dissemination of melanoma. *Sci. Rep.* **2017**, *7*, 1–12. [CrossRef]

101. Carreira, S.; Goodall, J.; Denat, L.; Rodriguez, M.; Nuciforo, P.; Hoek, K.S.; Testori, A.; LaRue, L.; Goding, C.R. Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. *Genes Dev.* **2006**, *20*, 3426–3439. [CrossRef]

102. Travnickova, J.; Wojciechowska, S.; Khamseh, A.; Gautier, P.; Brown, D.V.; Lefevre, T.; Brombin, A.; Ewing, A.; Capper, A.; Spitzer, M.; et al. Zebrafish MITF-Low Melanoma Subtype Models Reveal Transcriptional Subclusters and MITF-Independent Residual Disease. *Cancer Res.* **2019**, *79*, 5769–5784. [CrossRef]

103. Hoek, K.S.; Goding, C.R. Cancer stem cells versus phenotype-switching in melanoma. *Pigment. Cell Melanoma Res.* **2010**, *23*, 746–759. [CrossRef]

104. Johannes, L. The Cellular and Chemical Biology of Endocytic Trafficking and Intracellular Delivery—The GL-Lect Hypothesis. *Molecules* **2021**, *26*, 3299. [CrossRef] [PubMed]

105. Christenson, L. Steroidogenic acute regulatory protein (StAR) and the intramitochondrial translocation of cholester-ol. *Biochim. Biophys. Acta Mol. Cell Biol. Lipids* **2000**, *1529*, 175–187.

106. Wiedenmann, B.; Franke, W.W.; Kuhn, C.; Moll, R.; E Gould, V. Synaptophysin: A marker protein for neuroendocrine cells and neoplasms. *Proc. Natl. Acad. Sci. USA* **1986**, *83*, 3500–3504. [CrossRef] [PubMed]

107. Faillot, S.; Assie, G. ENDOCRINE TUMOURS: The genomics of adrenocortical tumors. *Eur. J. Endocrinol.* **2016**, *174*, R249–R265. [CrossRef]

108. Brondani, V.; Lacombe, A.; Mariani, B.; Montenegro, L.; Soares, I.; Bezerra-Neto, J.; Tanno, F.; Srougi, V.; Chambo, J.; Mendonca, B.; et al. Low Protein Expression of both ATRX and ZNRF3 as Novel Negative Prognostic Markers of Adult Adrenocortical Carcinoma. *Int. J. Mol. Sci.* **2021**, *22*, 1238. [CrossRef]

109. Bai, X.; Fisher, D.E.; Flaherty, K.T. Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways. *Nat. Rev. Clin. Oncol.* **2019**, *16*, 549–562. [CrossRef]